Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytosorbents CorpCTSO · Entity 7625 | Director | August 08, 2025 | August 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytosorbents Corp
Report date August 08, 2025 · Filed August 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2035-08-08 | Direct | 22,000 |
Reported balance
After 2025-08-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-08-08 · Grant · Acquired 22,000 · Balance 22,000 F2: The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date. |
| Common StockSEC Table I · non-derivative | Direct | 88,834 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 88,834 F1: Includes: (i) the following Restricted Stock Units ("RSUs") that will be settled into Common Stock vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 19,534 shares of Common Stock owned by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes: (i) the following Restricted Stock Units ("RSUs") that will be settled into Common Stock vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 19,534 shares of Common Stock owned by the reporting person.
F2: The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 08, 2025 Filed Aug 8, 2025 23:39 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001104659-25-075796 · tm2522995-1_4seq1.xml · derivative · entry 2 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2035-08-08 F2 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date. Read SEC document |
| April 02, 2024 Filed Apr 5, 2024 01:47 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (Right to Buy) · Derivative | 22,000 | Not disclosed Strike: $0.96 | Not disclosed |
DisclosureSEC source: 0001104659-24-043796 · tm2411149-6_4seq1.xml · derivative · entry 1 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · Not disclosed shares Expires 2034-04-02 F1 · price: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date. F1 · derivative.exercise_date: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 21:32 UTC | Cytosorbents Corp CTSO · Entity 7625 | PurchaseCommon Stock Warrant (Right to Buy) · Derivative | 2,631 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0001104659-23-126428 · tm2332958-7_4seq1.xml · derivative · entry 2 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,631 Underlying: Common Stock · 2,631 shares Expires 2028-12-13 F1 · kind: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant. F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 21:32 UTC | Cytosorbents Corp CTSO · Entity 7625 | PurchaseCommon Stock | 7,519 | $1.33 | $10,000.27 |
DisclosureSEC source: 0001104659-23-126428 · tm2332958-7_4seq1.xml · nonDerivative · entry 1 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,834 F1 · shares: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant. F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant. F2 · balance_after: Includes: (i) the following Restricted Stock Units ("RSUs") that will be settled into Common Stock vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 19,534 shares of Common Stock owned by the reporting person. Read SEC document |
| July 07, 2023 Filed Jul 12, 2023 00:30 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001104659-23-080102 · tm2321021-4_4seq1.xml · derivative · entry 2 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-07-07 F2 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options shall vest in full on the first anniversary of the award date, subject to the reporting person's continued service as of the applicable vesting date. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 22:51 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 18,975 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0001104659-22-090260 · tm2223355d8_4seq1.xml · derivative · entry 2 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,975 Underlying: Common Stock · 18,975 shares Expires 2032-08-10 F2 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four equal parts on 8/10/2022, 9/30/2022, 12/31/2022 and 3/31/2023, subject to the reporting person's continued service as of the applicable vesting date. Read SEC document |
| May 16, 2022 Filed May 17, 2022 20:44 UTC | Cytosorbents Corp CTSO · Entity 7625 | PurchaseCommon Stock | 1,676 | $2.24 | $3,748.54 |
DisclosureSEC source: 0001104659-22-061986 · tm2215854d1_4seq1.xml · nonDerivative · entry 1 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,315 Read SEC document |
| December 09, 2021 Filed Dec 14, 2021 00:59 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001104659-21-149251 · tm2135306-1_4seq1.xml · derivative · entry 3 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2022-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2021 Filed Dec 14, 2021 00:59 UTC | Cytosorbents Corp CTSO · Entity 7625 | Tax withholdingCommon Stock | 3,161 | $5.22 | $16,500.42 |
DisclosureSEC source: 0001104659-21-149251 · tm2135306-1_4seq1.xml · nonDerivative · entry 2 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,639 Read SEC document |
| December 09, 2021 Filed Dec 14, 2021 00:59 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 4,000 | $4.13 | $16,500.00 |
DisclosureSEC source: 0001104659-21-149251 · tm2135306-1_4seq1.xml · nonDerivative · entry 1 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2021 Filed Apr 15, 2021 01:15 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 17,250 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0001104659-21-050400 · tm2113016d6_4.xml · derivative · entry 1 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,250 Underlying: Common Stock · 17,250 shares Expires 2031-04-12 F1 · derivative.exercise_date: The stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying the stock options will vest in four equal parts on 4/12/2021, 6/30/2021, 9/30/2021 and 12/31/2021, subject to the reporting person's continued service as of the applicable vesting date. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 20:10 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001104659-20-097228 · tm2029102-1_4.xml · derivative · entry 2 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 20:10 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 4,000 | $3.35 | $13,400.00 |
DisclosureSEC source: 0001104659-20-097228 · tm2029102-1_4.xml · nonDerivative · entry 1 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 9,500 shares of common stock owned by the reporting person. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:00 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $6.03 | $0.00 |
DisclosureSEC source: 0001104659-20-028652 · tm2011575d6_form4.xml · derivative · entry 1 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-02-28 F1 · derivative.exercise_date: Includes 15,000 stock options granted on 2/28/2020 and reported on this Form 4. These options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan and will vest in four equal parts on 3/31/2020, 6/30/2020, 9/30/2020 and 12/31/2020. F1 · balance_after: Includes 15,000 stock options granted on 2/28/2020 and reported on this Form 4. These options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan and will vest in four equal parts on 3/31/2020, 6/30/2020, 9/30/2020 and 12/31/2020. Read SEC document |
| July 22, 2019 Filed Jul 25, 2019 00:17 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $7.33 | $0.00 |
DisclosureSEC source: 0001144204-19-035837 · tv525803_4.xml · derivative · entry 1 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-07-22 F1 · derivative.exercise_date: Such options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan and vest in four equal parts at the end of each calendar quarter. The grant gives effect to vesting which was to occur on March 31, 2019 and June 30, 2019. The remaining portion of the grant will vest on September 30, 2019 and December 31, 2019. Read SEC document |
| August 14, 2018 Filed Feb 14, 2019 22:20 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001144204-19-008362 · tv513835_5.xml · derivative · entry 4 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,200 shares Expires 2018-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2018 Filed Feb 14, 2019 22:20 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 1,200 | $2.00 | $2,400.00 |
DisclosureSEC source: 0001144204-19-008362 · tv513835_5.xml · nonDerivative · entry 2 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (a) the following restricted stock units subject to vesting upon a "Change in Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (i) 3,300 restricted stock units granted on March 15, 2018, (ii) 6,000 restricted stock units granted on February 24, 2017, (iii) 5,000 restricted stock units granted on June 7, 2016, and (iv) 55,000 restricted stock units granted on April 8, 2015, and (b) 5,500 shares of common stock owned by the reporting person. Read SEC document |
| May 31, 2018 Filed Feb 14, 2019 22:20 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (right to buy) · Derivative | 1,800 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001144204-19-008362 · tv513835_5.xml · derivative · entry 3 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,800 shares Expires 2018-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2018 Filed Feb 14, 2019 22:20 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 1,800 | $0.88 | $1,575.00 |
DisclosureSEC source: 0001144204-19-008362 · tv513835_5.xml · nonDerivative · entry 1 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (a) the following restricted stock units subject to vesting upon a "Change in Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (i) 3,300 restricted stock units granted on March 15, 2018, (ii) 6,000 restricted stock units granted on February 24, 2017, (iii) 5,000 restricted stock units granted on June 7, 2016, and (iv) 55,000 restricted stock units granted on April 8, 2015, and (b) 5,500 shares of common stock owned by the reporting person. Read SEC document |
| March 15, 2018 Filed Apr 27, 2018 15:41 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 14,450 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001144204-18-022968 · tv492275_4.xml · derivative · entry 2 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,450 Underlying: Common Stock · 14,450 shares Expires 2028-03-15 F3 · derivative.exercise_date: Such options were granted pursuant to the Plan and vest in four equal parts at the end of each calendar quarter beginning January 1, 2018. Read SEC document |
| March 15, 2018 Filed Apr 27, 2018 15:41 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantCommon Stock | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-022968 · tv492275_4.xml · nonDerivative · entry 1 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,800 F1 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change in Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"). F2 · balance_after: Includes (a) the following restricted stock units subject to vesting in accordance with the schedule set forth in (1) above: (i) 3,300 restricted stock units granted on March 15, 2018 and reported on this Form 4, (ii) 6,000 restricted stock units granted on February 24, 2017, (iii) 5,000 restricted stock units granted on June 7, 2016, and (iv) 55,000 restricted stock units granted on April 8, 2015, and (b) 2,500 shares of common stock owned by the reporting person. Read SEC document |
| June 08, 2017 Filed Jun 8, 2017 22:37 UTC | Cytosorbents Corp CTSO · Entity 7625 | PurchaseCommon Stock | 2,000 | $4.00 | $7,999.00 |
DisclosureSEC source: 0001144204-17-031784 · v468718_4.xml · nonDerivative · entry 2 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,500 F1 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 6,000 RSUs granted on February 24, 2017, (b) 5,000 RSUs granted on June 7, 2016, and (c) 55,000 RSUs granted on April 8, 2015, and (ii) 2,500 shares of common stock purchased by the reporting person in the open market and reported on this Form 4. Read SEC document |
| June 08, 2017 Filed Jun 8, 2017 22:37 UTC | Cytosorbents Corp CTSO · Entity 7625 | PurchaseCommon Stock | 500 | $3.98 | $1,987.50 |
DisclosureSEC source: 0001144204-17-031784 · v468718_4.xml · nonDerivative · entry 1 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 22:19 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 13,750 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001144204-17-011830 · v460707_4.xml · derivative · entry 2 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2027-02-24 F3 · derivative.exercise_date: Such options were granted pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, which vest in four equal parts at the end of each calendar quarter beginning April 1, 2017. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 22:19 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-011830 · v460707_4.xml · nonDerivative · entry 1 Jones Edward Raymond · CIK 0001396246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 F1 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan. F2 · balance_after: Includes (i) 6,000 restricted stock units granted on February 24, 2017 and reported on this Form 4, (ii) 5,000 restricted stock units granted on June 7, 2016, subject to vesting in accordance with the schedule set forth in (1) above and (iii) 55,000 restricted stock units granted on April 8, 2015, subject to vesting in accordance with the schedule set forth in (1) above. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.